ArticleHepatology international2022
A new risk stratification strategy for fatty liver disease by incorporating MAFLD and fibrosis score in a large US population.
Article in Hepatology international, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Metabolic (dysfunction)-associated fatty liver disease metrics and contributions to liver research.Hepatology international · 2024Pooled it
- Single-port robotic versus single-incision laparoscopic cholecystectomy in patients with BMI ≥ 25 kg/mJournal of robotic surgery · 2024Pooled it
- Global epidemiology of type 2 diabetes in patients with NAFLD or MAFLD: a systematic review and meta-analysis.BMC medicine · 2024Pooled it
- Current understanding and future perspectives on the impact of changing NAFLD to MAFLD on global epidemiology and clinical outcomes.Hepatology international · 2023Pooled it
- Triglycerides/high-density lipoprotein-cholesterol ratio outperforms traditional lipid indicators in predicting metabolic dysfunction-associated steatotic liver disease among U.S. adults.Frontiers in endocrinology · 2025Article
- NAFLD and MAFLD independently increase the risk of major adverse cardiovascular events (MACE): a 20-year longitudinal follow-up study from regional Australia.Hepatology international · 2024Article
- Performance of noninvasive seromarkers in predicting liver fibrosis among MAFLD patients with or without viral hepatitis.The Kaohsiung journal of medical sciences · 2024Article
- Intra-gastric balloon with lifestyle modification: a promising therapeutic option for overweight and obese patients with metabolic dysfunction-associated steatotic liver disease.Internal and emergency medicine · 2023Article
- Adding to the confusion in more than just the name.Clinical and molecular hepatology · 2023Article
- Furthering research on MAFLD: the APASL Metabolic fAtty lIver DiseasE coNsortium (MAIDEN).Hepatology international · 2023Article
- Association between metabolically healthy overweight/obesity and gallstones in Chinese adults.Nutrition & metabolism · 2023Article
- Article
- MAFLD: How is it different from NAFLD?Clinical and molecular hepatology · 2023Review
- Metabolic dysfunction associated fatty liver disease: The new nomenclature and its impact.World journal of gastroenterology · 2023Article
- Metabolic dysfunction-associated fatty liver disease and implications for cardiovascular risk and disease prevention.Cardiovascular diabetology · 2022Review
- MAFLD: what 2 years of the redefinition of fatty liver disease has taught us.Therapeutic advances in endocrinology and metabolism · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundMetabolic dysfunction-associated fatty liver disease (MAFLD) is a newly proposed definition of fatty liver disease (FLD) independent of excessive alcohol consumption (EAC) and hepatitis viral infection. Evidence on the mortality risk in different types of FLD [nonalcoholic FLD (NAFLD), alcoholic FLD (AFLD), and MAFLD] is sparse, hindering the identification of high-risk populations for preferential clinical surveillance.
methodsA total of 11,000 participants in the Third National Health and Nutrition Examination Survey were enrolled. Participants were categorized into three groups [FLD( - ), MAFLD( - ), and MAFLD( +)] according to FLD and MAFLD criteria, and further categorized into six groups by EAC. Multivariate Cox proportional hazard model was used to estimate the risk of all-cause, cardiovascular-related, and cancer-related mortality.
resultsDuring a median follow-up of 23.2 years, a total of 3240 deaths were identified. Compared with FLD( - )/EAC( - ) participants, MAFLD( +) individuals had higher all-cause mortality risk [hazard ratio (HR) = 1.28, 95% confidence interval (CI) = 1.18-1.39] regardless of EAC status [MAFLD( +)/NAFLD: HR = 1.22, 95%CI = 1.11-1.34; MAFLD( +)/AFLD: HR = 1.83, 95%CI = 1.46-2.28], while not for MAFLD( - ) individuals. Furthermore, diabetes-driven-MAFLD had higher mortality risk (HR = 2.00, 95%CI = 1.77-2.27) followed by metabolic dysregulation-driven-MAFLD (HR = 1.30, 95%CI = 1.06-1.60) and overweight/obesity-driven-MAFLD (HR = 1.11, 95%CI = 1.00-1.22). Additionally, MAFLD( - ) participants with elevated fibrosis score were also associated with statistically significantly higher mortality risk (HR = 3.23, 95%CI = 1.63-6.40).
conclusionsUtilizing a representative sample of the US population, we proved the validity of MAFLD subtype and fibrosis score, rather than the traditional definition (NAFLD and AFLD), in the risk stratification of FLD patients. These findings may be applied to guide the determination of surveillance options for FLD patients.
Indexed as
Identifiers
35701716What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.